FGF1 ameliorates obesity‐associated hepatic steatosis by reversing IGFBP2 hypermethylation
The FASEB Journal · 2023
DOI: 10.1096/fj.202201950r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Jie Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China. Hauptthemen laut MEDLINE: Fibroblast Growth Factor 1, Insulin Resistance, Non-alcoholic Fatty Liver Disease, Obesity. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Obesity is a major contributing factor for metabolic‐associated fatty liver disease (MAFLD). Fibroblast growth factor (FGF) 1 is the first paracrine FGF family member identified to exhibit promising metabolic regulatory properties capable of conferring glucose‐lowering and insulin‐sensitizing effect. This study explores the role and molecular underpinnings of FGF1 in obesity‐associated hepatic steatosis. In a mouse high‐fat diet (HFD)‐induced MAFLD model, chronic treatment with recombinant FGF1(rFGF1) was found to effectively reduce the severity of insulin resistance, hyperlipidemia, and inflammation. FGF1 treatment decreased lipid accumulation in the mouse liver and palmitic acid‐treated AML12 cells. These effects were associated with decreased mature form SREBF1 expression and its target genes FASN and SCD1. Interestingly, we uncovered that rFGF1 significantly induced IGFBP2 expression at both mRNA and protein levels in HFD‐fed mouse livers and cultured hepatocytes treated with palmitic acid. Adeno‐associated virus‐mediated IGFBP2 suppression significantly diminished the therapeutic benefit of rFGF1 on MAFLD‐associated phenotypes, indicating that IGFBP2 plays a crucial role in the FGF1‐mediated reduction of hepatic steatosis. Further analysis revealed that rFGF1 treatment reduces the recruitment of DNA methyltransferase 3 alpha to the IGFBP2 genomic locus, leading to decreased IGFBP2 gene methylation and increased mRNA and protein expression. Collectively, our findings reveal FGF1 modulation of lipid metabolism via epigenetic regulation of IGFBP2 expression, and unravel the therapeutic potential of the FGF1‐IGFBP2 axis in metabolic diseases associated with obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
- International Collaborative Center on Growth Factor Research, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
- Medical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Jin-San Zhang
Zitieren
APA
Wang, J., Zhang, F., Yang, W., Gao, D., Yang, L., Yu, C., Chen, C., Li, X., & Zhang, J. S. (2023). FGF1 ameliorates obesity‐associated hepatic steatosis by reversing IGFBP2 hypermethylation. The FASEB Journal. https://doi.org/10.1096/fj.202201950r
Vancouver
Wang J, Zhang F, Yang W, Gao D, Yang L, Yu C, et al. FGF1 ameliorates obesity‐associated hepatic steatosis by reversing IGFBP2 hypermethylation. The FASEB Journal. 2023. doi:10.1096/fj.202201950r
BibTeX
@article{Wang2023,
author = {Wang, Jie and Zhang, Feng and Yang, Weiwei and Gao, Dandan and Yang, Linglong and Yu, Chenhua and Chen, Chengshui and Li, Xiaokun and Zhang, Jin-San},
title = {FGF1 ameliorates obesity‐associated hepatic steatosis by reversing IGFBP2 hypermethylation},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202201950r}
}
EUVIMED